← Hanwha overview

Hanwha vs Zhejiang Jianfeng: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hanwha (000880.KO)

Q3 2026
▲4

Hanwha's US expansion and crypto push drive growth

  • US solar partnership boosts Qcells demand Hanwha's Qcells will supply solar modules for Chrysalis Renewables' first US projects under a partnership targeting over 3.5GW of solar and battery storage. This locks in long-term demand for Hanwha's products, supporting revenue growth and investor confidence.

    This is a new event that directly increases demand for Hanwha's solar products, a key business line.

  • Hanwha Power's first US compressor order Hanwha Power commissioned its first US fuel gas compressors and signed a 9-year service agreement. This proves its equipment works in the US market and opens a recurring service revenue stream, strengthening its power business.

    New contract and service agreement show Hanwha's expansion into the US power market, a positive for future earnings.

  • Hanwha's Philadelphia shipyard gets US backing JPMorgan and the Trump administration are supporting US shipbuilding, with Hanwha's Philadelphia yard at the center. Hanwha plans to invest $5 billion and hire 10,000 workers, benefiting from rising defense spending and government partnerships.

    This highlights Hanwha's strategic role in US defense and shipbuilding, with major investment and job creation that could boost its profile and orders.

  • Hanwha's $800M Ambarella deal and crypto platform Hanwha signed a long-term agreement with Ambarella worth over $800 million and is building a blockchain tokenization platform on Avalanche. These moves diversify into high-growth tech and digital assets, potentially adding new revenue streams.

    Both are new developments that show Hanwha's expansion into technology and crypto, which could drive future growth and investor interest.

July 2026
▲4

Hanwha's US expansion and crypto push drive growth

  • US solar partnership boosts Qcells demand Hanwha's Qcells will supply solar modules for Chrysalis Renewables' first US projects under a partnership targeting over 3.5GW of solar and battery storage. This locks in long-term demand for Hanwha's products, supporting revenue growth and investor confidence.

    This is a new event that directly increases demand for Hanwha's solar products, a key business line.

  • Hanwha Power's first US compressor order Hanwha Power commissioned its first US fuel gas compressors and signed a 9-year service agreement. This proves its equipment works in the US market and opens a recurring service revenue stream, strengthening its power business.

    New contract and service agreement show Hanwha's expansion into the US power market, a positive for future earnings.

  • Hanwha's Philadelphia shipyard gets US backing JPMorgan and the Trump administration are supporting US shipbuilding, with Hanwha's Philadelphia yard at the center. Hanwha plans to invest $5 billion and hire 10,000 workers, benefiting from rising defense spending and government partnerships.

    This highlights Hanwha's strategic role in US defense and shipbuilding, with major investment and job creation that could boost its profile and orders.

  • Hanwha's $800M Ambarella deal and crypto platform Hanwha signed a long-term agreement with Ambarella worth over $800 million and is building a blockchain tokenization platform on Avalanche. These moves diversify into high-growth tech and digital assets, potentially adding new revenue streams.

    Both are new developments that show Hanwha's expansion into technology and crypto, which could drive future growth and investor interest.

Latest
▲4

Hanwha's US expansion and crypto push drive growth

  • US solar partnership boosts Qcells demand Hanwha's Qcells will supply solar modules for Chrysalis Renewables' first US projects under a partnership targeting over 3.5GW of solar and battery storage. This locks in long-term demand for Hanwha's products, supporting revenue growth and investor confidence.

    This is a new event that directly increases demand for Hanwha's solar products, a key business line.

  • Hanwha Power's first US compressor order Hanwha Power commissioned its first US fuel gas compressors and signed a 9-year service agreement. This proves its equipment works in the US market and opens a recurring service revenue stream, strengthening its power business.

    New contract and service agreement show Hanwha's expansion into the US power market, a positive for future earnings.

  • Hanwha's Philadelphia shipyard gets US backing JPMorgan and the Trump administration are supporting US shipbuilding, with Hanwha's Philadelphia yard at the center. Hanwha plans to invest $5 billion and hire 10,000 workers, benefiting from rising defense spending and government partnerships.

    This highlights Hanwha's strategic role in US defense and shipbuilding, with major investment and job creation that could boost its profile and orders.

  • Hanwha's $800M Ambarella deal and crypto platform Hanwha signed a long-term agreement with Ambarella worth over $800 million and is building a blockchain tokenization platform on Avalanche. These moves diversify into high-growth tech and digital assets, potentially adding new revenue streams.

    Both are new developments that show Hanwha's expansion into technology and crypto, which could drive future growth and investor interest.

Zhejiang Jianfeng Group Co Ltd (600668.CG)

Q3 2026
▲3▼1

Drug approvals build pipeline, but interim loss and weak revenue weigh

  • New drug approvals expand pharmaceutical pipeline Jianfeng's drug subsidiary won Chinese approval for two new products: injectable tedizolid phosphate (a hospital antibiotic) and compound tropicamide eye drops, which are already on the national reimbursement and essential drug lists. Each approval adds a future sales stream, supporting the shares.

    Two fresh regulatory approvals are the clearest new positive for the company's pharma business.

  • Methyldopa API cleared for China and Europe The subsidiary's methyldopa ingredient was approved for domestic sale, then won a European CEP certificate letting it enter the EU and other markets that accept it. This opens export revenue for a mature blood-pressure drug, a modest but real growth driver.

    The domestic and European methyldopa approvals are new and directly widen the company's market.

  • Products proposed for national drug procurement Jianfeng was among Shanghai-listed drugmakers saying its products were proposed for selection in China's 12th national centralized procurement round. Winning government bulk-buying contracts usually means large guaranteed volumes, though at lower prices, so it lifts sales expectations.

    Selection in national procurement is a new, concrete demand signal for the company's drugs.

  • Interim report swings to a loss as revenue falls First-half revenue dropped 10.33% to 1.165 billion yuan and the company swung from profit to a net loss of 8.95 million yuan. This is the main counterweight: the core business is shrinking and unprofitable, which pressures the share price despite the drug approvals.

    The loss is the biggest new negative and offsets the positive pipeline news.

August 2026
▲3▼1

Drug approvals build pipeline, but interim loss and weak revenue weigh

  • New drug approvals expand pharmaceutical pipeline Jianfeng's drug subsidiary won Chinese approval for two new products: injectable tedizolid phosphate (a hospital antibiotic) and compound tropicamide eye drops, which are already on the national reimbursement and essential drug lists. Each approval adds a future sales stream, supporting the shares.

    Two fresh regulatory approvals are the clearest new positive for the company's pharma business.

  • Methyldopa API cleared for China and Europe The subsidiary's methyldopa ingredient was approved for domestic sale, then won a European CEP certificate letting it enter the EU and other markets that accept it. This opens export revenue for a mature blood-pressure drug, a modest but real growth driver.

    The domestic and European methyldopa approvals are new and directly widen the company's market.

  • Products proposed for national drug procurement Jianfeng was among Shanghai-listed drugmakers saying its products were proposed for selection in China's 12th national centralized procurement round. Winning government bulk-buying contracts usually means large guaranteed volumes, though at lower prices, so it lifts sales expectations.

    Selection in national procurement is a new, concrete demand signal for the company's drugs.

  • Interim report swings to a loss as revenue falls First-half revenue dropped 10.33% to 1.165 billion yuan and the company swung from profit to a net loss of 8.95 million yuan. This is the main counterweight: the core business is shrinking and unprofitable, which pressures the share price despite the drug approvals.

    The loss is the biggest new negative and offsets the positive pipeline news.

Latest
▲3▼1

Drug approvals build pipeline, but interim loss and weak revenue weigh

  • New drug approvals expand pharmaceutical pipeline Jianfeng's drug subsidiary won Chinese approval for two new products: injectable tedizolid phosphate (a hospital antibiotic) and compound tropicamide eye drops, which are already on the national reimbursement and essential drug lists. Each approval adds a future sales stream, supporting the shares.

    Two fresh regulatory approvals are the clearest new positive for the company's pharma business.

  • Methyldopa API cleared for China and Europe The subsidiary's methyldopa ingredient was approved for domestic sale, then won a European CEP certificate letting it enter the EU and other markets that accept it. This opens export revenue for a mature blood-pressure drug, a modest but real growth driver.

    The domestic and European methyldopa approvals are new and directly widen the company's market.

  • Products proposed for national drug procurement Jianfeng was among Shanghai-listed drugmakers saying its products were proposed for selection in China's 12th national centralized procurement round. Winning government bulk-buying contracts usually means large guaranteed volumes, though at lower prices, so it lifts sales expectations.

    Selection in national procurement is a new, concrete demand signal for the company's drugs.

  • Interim report swings to a loss as revenue falls First-half revenue dropped 10.33% to 1.165 billion yuan and the company swung from profit to a net loss of 8.95 million yuan. This is the main counterweight: the core business is shrinking and unprofitable, which pressures the share price despite the drug approvals.

    The loss is the biggest new negative and offsets the positive pipeline news.